ALSYMPCA Trial: Updated Analysis of Survival With Radium-223 Treatment in Metastatic Prostate Cancer 


Get Permission

In a trial (ALSYMPCA trial) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, UK, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and bone metastases.1 Interim analysis showed that radium-223 treatment was associated with significantly prolonged overall survival, resulting in termination of the trial. An updated analysis, performed before crossover of the control group to radium-223 treatment, confirmed the overall survival advantage.

Study Details

In this phase III double-blind trial, 921 patients who had received, were not eligible to receive, or declined docetaxel were randomly assigned to receive six injections of radium-223 at a dose of 50 kBq/kg (n = 614) or matching placebo (n = 307), one injection every 4 weeks, with all patients also receiving the best standard of care.

Patients in the radium-223 and placebo groups were well matched for age (median, 71 years in both), race (94% white in both), total alkaline phosphatase levels (< 220 U/L in 57% and 55%), current bisphosphonate use (41% and 40%), any previous use of docetaxel (57% in both), ECOG performance status (0 or 1 in 87% and 86%), WHO cancer pain ladder score (1 in 42% and 45%), extent of disease (6–20 metastases in 43% and 48%, >20 in 32% and 30%), and receipt of external-beam radiation therapy within 12 weeks after screening (16% in both). Median levels of hemoglobin, albumin, total alkaline phosphatase, and prostate-specific antigen (PSA) were similar at baseline.

Significantly Improved Overall Survival

A prespecified interim analysis involving 809 patients showed that radium-223 treatment was associated with significantly prolonged overall survival compared with placebo (median, 14.0 vs 11.2 months, hazard ratio [HR] = 0.70, P = .002). An updated analysis in all 921 patients, performed before crossover from placebo to radium-223, showed a similar survival advantage for radium-223 treatment (median, 14.9 vs 11.3 months, HR = 0.70, P < .001).

The investigators found no significant heterogeneity among subgroups, including those with baseline total alkaline phosphatase ≥ 220 U/L, with and without current bisphosphonate use, with and without previous docetaxel use, with performance status of 0 or 1, with 6 to 20 and > 20 metastases, and with or without opioid use. Thus, the evidence suggests that the benefit of radium-223 is consistent across all subgroups examined.

All main secondary efficacy endpoints supported the benefit of radium-223, including significantly prolonged time to first symptomatic skeletal event (median, 15.6 vs 9.8 months, HR = 0.66, P < .001), time to increase in total alkaline phosphatase level (HR = 0.17, P < .001), and time to increase in PSA level (HR = 0.64, P < .001). In addition, significantly more radium-223 recipients had alkaline phosphatase response (≥ 30% reduction, P < .001) and normalization of total alkaline phosphatase level (P < .001). A ≥ 30% reduction in PSA blood levels at week 12 occurred in more patients in the radium-223 group (16% vs 6%, P < .001), with this reduction being sustained 4 weeks after the last injection in more radium-223 patients (14% vs 4%, P < .001).

Safety

Radium-223 treatment was associated with lower rates of any adverse event (93% vs 96%, grade 3 or 4 adverse events (56% vs 62%), serious adverse events (47% vs 60%), and adverse events leading to study drug discontinuation (16% vs 21%).

Hematologic adverse events of grade 3 or higher included anemia in 13% of patients in both groups, thrombocytopenia in 6.5% and 2%, and neutropenia in 3% and 1%. Grade 3 febrile neutropenia occurred in one patient in each group. The most common nonhematologic adverse events of grade 3 or higher were bone pain (21% in the radium-223 group and 26% in the placebo group), fatigue (5% and 6%), and spinal cord compression (3.5% and 6%). Serious adverse events that occurred in ≥ 5% of patients in the radium-223 group or the placebo group consisted of bone pain (10% and 16%), anemia (8% and 9%), and spinal cord compression (4% and 5%).

Assessment of quality of life using the Functional Assessment of Cancer Therapy–Prostate (FACT-P) questionnaire showed that more patients in the radium-223 group had meaningful improvement (≥ 10 point increase in score) during treatment (25% vs 16%, P = .02) and that the radium-223 group had a smaller reduction in score from baseline to week 16 (mean change, −2.7 vs −6.8, P = .006).

The investigators noted, “The treatment of prostate cancer has evolved since the trial began, with new data on the use of cabazitaxel [Jevtana Kit], abiraterone [Zytiga], and enzalutamide [Xtandi] in patients who have received docetaxel. The excellent safety profile of radium-223 and the non-overlapping mechanism of action make radium-223 potentially suitable for use either sequentially or in combination with these other agents.” A phase I/II trial of radium-223 combined with docetaxel in patients with castration-resistant prostate cancer and bone metastases is underway (ClinicalTrials.gov number, NCT01106352). ■

Disclosure: The trial was funded by Algeta and Bayer HealthCare Pharmaceuticals.

Reference

1. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013


Related Articles

COMMENTARY: Radium-223 and Beyond in Metastatic Castration-Resistant Prostate Cancer

Metastasis to bone is the hallmark of prostate cancer and a major source of disease-related morbidity and mortality. In addition to prostate cancer cells, other major players in the vicious interactive cycle of prostate cancer bone metastasis are osteoblasts, osteoclasts, and mineralized bone...


Advertisement

Advertisement



Advertisement